Alphabet's GV Leads Funding in Gene Editing Company Verve Therapeutics

GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.

from NDTV Gadgets - Latest http://bit.ly/2DTO11A
via

Comments

Popular posts from this blog

Coinbase to Ramp Up Web3 Initiatives in the UK as Japan, Dubai Race to Become Blockchain Hubs

Oppo K11 5G With Snapdragon 782G SoC, 100W Fast Charging Launched: Price, Specifications

Instagram Testing Group-Tagging Feature via Single Mention on Stories: Report